Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in Patients With Extensive Transurethrally Unresectable Very-high-risk NMIBC?

NCT07625527 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Bladder (Urothelial, Transitional Cell) Cancer
Non Muscle Invasive Bladder Cancer

Interventions

BEHAVIORAL: Active Surveillance
DRUG: PD-1/PD-L1 Inhibitor-Based Systemic Immunotherapy

Sponsor

Tianjin Medical University Second Hospital